ReachRxResearch
Home
Research
Sign Up
Artificial intelligence for clinical decision-making in retinal disorders: From screening and diagnosis to treatment and longitudinal management
Back to Research Hub
  1. Home
  2. Research Hub
  3. Artificial intelligence for clinical dec…

Artificial intelligence for clinical decision-making in retinal disorders: From screening and diagnosis to treatment and longitudinal management

Progress in Retinal and Eye Research·September 29Open Access
OphthalmologyLimited evidenceDiabetic Macular EdemaDiabetic RetinopathyInherited Retinal DiseaseNeovascular Age-Related Macular DegenerationNarrative ReviewArtificial IntelligenceRetinal ImagingAdult

Summary

View source

What was studied

This narrative review examined AI-based clinical decision support across four retinal disease settings: diabetic retinopathy (DR) screening and referral, diabetic macular edema (DME) treatment assessment, neovascular age-related macular degeneration (nAMD) retreatment and longitudinal monitoring, and inherited retinal disease (IRD) diagnosis, genotype-phenotype support, progression modeling, and trial enrichment.

Key findings

Evidence is strongest for DR screening (supported by prospective and real-world validation), while treatment-oriented AI applications in DME and nAMD, and multimodal diagnostic/prognostic tools in IRDs, remain inconsistently validated and lack robust clinical utility data.

Study limitations

As a narrative review, it does not perform systematic search or meta-analysis, limiting reproducibility; the review does not quantify pooled performance metrics across included studies; translational gaps between model performance and real-world clinical utility are acknowledged but not resolved.

Clinical implications

AI-assisted DR screening is the most clinically ready application and can support referral decisions with real-world evidence; clinicians should be cautious about adopting AI tools for DME/nAMD treatment decisions or IRD diagnosis outside of validated, prospectively evaluated workflows.

Caveats

  • AI tools discussed are at varying stages of clinical readiness; findings should not be generalized to imply regulatory approval or routine clinical adoption across all applications
  • The evidence base across the four disease areas is highly heterogeneous in study design and validation rigor, making cross-condition comparisons difficult
  • This is a narrative review without systematic search methods or meta-analysis; conclusions reflect the authors' synthesis and may not capture the full body of evidence

Related Questions

Explore related topics

What is the clinical validation evidence for AI-based diabetic retinopathy screening tools in real-world settings?How does AI support treatment decisions in neovascular age-related macular degeneration monitoring and retreatment?What are the current AI approaches for inherited retinal disease diagnosis and genotype-phenotype prediction?

Publication Details

Year
2026
Journal
Progress in Retinal and Eye Research
Source
View article
Keep scrolling
More content below.
Up Next